MSCs are adult stem cells found in connective tissues such as bone marrow, fat, and umbilical cord. Like all stem cells, they can copy themselves (self-renewal) and give rise to more specialized cells (differentiation). They are multipotent: in the laboratory, they reliably form bone, cartilage, and fat cells.
The name comes from the mesenchyme, the loose connective tissue of the early embryo that later forms bone, cartilage, muscle, fat, and blood vessels. Many researchers now prefer the term mesenchymal stromal cells, because not every cell in an MSC preparation meets the strict definition of a stem cell. The abbreviation stays the same.
In 2006, the International Society for Cellular Therapy (ISCT) set three minimum criteria that a cell population must meet to be called MSCs. These criteria let laboratories around the world compare their work.
Early researchers expected MSCs to repair tissue by turning into new cells. Some laboratory studies have reported MSCs forming cell types outside their usual range, such as nerve or liver cells, but whether this happens in the body, and whether it matters for treatment, is disputed.
Later work changed the picture. Few infused MSCs survive in the body for long, and most of their effect comes from the molecules they release. In laboratory and animal studies, these signals lower inflammation, adjust immune cell activity, support the growth of new blood vessels, and limit scarring. For this reason, Arnold Caplan, the scientist who named MSCs, proposed in 2017 calling them medicinal signaling cells. Much of this signaling travels in exosomes, tiny vesicles that cells use to communicate.
MSCs carry low levels of the surface molecules that trigger immune rejection. That is why cells from one screened donor can be given to a different patient, which is called allogeneic use.
Low immunogenicity is not the same as invisibility. Researchers describe MSCs as immune evasive rather than immune privileged: the immune system can still recognize and clear donor cells over time. This is one reason their effects are attributed to the signals they release in the window before they are cleared.
| Source | How cells are collected | Notes |
|---|---|---|
| Bone marrow | Needle aspiration, usually from the pelvis | The most studied source. Requires a procedure on the patient or donor |
| Fat (adipose) tissue | Liposuction | Yields many cells. Requires a procedure |
| Umbilical cord tissue | From the cord's Wharton's jelly, after birth, with consent | No procedure on mother or baby. The tissue would otherwise be discarded |
| Placenta | After birth, with consent | Less studied than cord tissue |
| Dental pulp | From extracted teeth | Mainly a research source |
| Synovial fluid and membrane | From the joint lining | Mainly a research source |
| Mesenchymal stem cells (MSCs) | Hematopoietic stem cells (HSCs) | |
|---|---|---|
| What they form | Bone, cartilage, fat, and connective tissue cells | All blood and immune cells |
| Main sources | Bone marrow, fat, umbilical cord tissue | Bone marrow, mobilized blood, umbilical cord blood |
| Main medical use | Research and approved uses in immune conditions. Widely studied in tissue repair | Bone marrow and cord blood transplants for blood cancers and blood disorders |
| Effect on the immune system | Adjust immune activity | Rebuild the immune system after a transplant |
Thousands of clinical trials have registered MSC treatments. The evidence differs widely by condition.
In knee osteoarthritis, randomized trials, including one using UC-MSCs, have reported less pain than with hyaluronic acid, without clear changes in cartilage on MRI. In autoimmune conditions such as rheumatoid arthritis, lupus, Crohn’s disease, and multiple sclerosis, trials are mostly small and their results mixed. In neurological conditions such as stroke, Parkinson’s disease, ALS, and spinal cord injury, most trials are early-phase and focused on safety. MSCs are also being studied in lung disease, liver disease, diabetes, and chronic wounds.
Outside the approved uses, MSC therapy is investigational. Our medical team evaluates UC-MSC protocols in the areas of clinical focus listed on our site, case by case.
A 2021 meta-analysis of 62 randomized trials with 3,546 participants linked MSC treatment to transient fever, administration-site reactions, constipation, fatigue, and sleeplessness. A 2020 meta-analysis found no increased risk of infection, blood clots, death, or malignancy.
Researchers still face several open problems. MSCs from different sources and laboratories behave differently, which makes trials hard to compare. Isolation and expansion methods are not standardized, and the best dose and route for most conditions are unknown. Large, well-controlled trials are still needed for most uses.
Start with a medical review
Whether UC-MSC therapy fits your case is a medical decision. At OmniStem, it starts with a physician reviewing your records through the Regenerative Evaluation.
Start Your EvaluationDominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Translational Medicine. 2017;6(6):1445-1451.
Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nature Biotechnology. 2014;32(3):252-260.
Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical cord as prospective source for mesenchymal stem cell-based therapy. Stem Cells International. 2016;2016:6901286.
Matas J, Orrego M, Amenabar D, et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Stem Cells Translational Medicine. 2019;8(3):215-224.
Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Research & Therapy. 2021;12:545.
Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. eClinicalMedicine. 2020;19:100249.